Skip to main content

Design Therapeutics (US:DSGN) — Company Overview, News & Financial Data

Design Therapeutics logo
DSGNDesign Therapeutics
Design Therapeutics primary media
Company profile

Design Therapeutics

About

Explore United States companies

Design Therapeutics (NASDAQ:DSGN) is a biotechnological firm dedicated to developing treatments for genetic diseases. Focused primarily on addressing the root causes of these diseases, the company leverages its innovative platform to create therapies that target and correct genetic aberrations. Its projects span a variety of conditions, with a particular emphasis on degenerative disorders. By pursuing a blend of cutting-edge science and patient-centric research, Design Therapeutics aims to fulfill its objective of delivering transformative genetic medicines that can vastly improve the lives of patients worldwide.

Snapshot

Public USOwnership
2017Year founded
58Employees
Carlsbad, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Carlsbad, US

Products and/or services of Design Therapeutics

  • GeneTAC platform, a proprietary technology for developing medicines to treat genetic disorders by precisely modulating gene expression.
  • DT-216 for Friedreich's ataxia, aiming to increase frataxin protein levels for symptomatic relief and disease modification.
  • Preclinical programs focused on addressing nucleotide repeat disorders, targeting diseases like myotonic dystrophy.
  • Partnerships in gene editing and therapy development, leveraging unique technologies for novel therapeutic products.
  • Investment in novel drug delivery systems, enhancing the precision and efficiency of gene-targeted treatments.
  • Research on small molecule therapies for addressing genetic mutations and restoring normal gene function.

Design Therapeutics executive team

  • Mr. Pratik Shah Ph.D.Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
  • Dr. Sean Jeffries Ph.D.Chief Operating Officer
  • Dr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific Advisor
  • Ms. Julie D. Burgess CPAChief Accounting Officer
  • Mr. Doane Chilcoat Ph.D.Chief Technology Officer
  • Mr. Mustapha ParekhGeneral Counsel
  • Dr. Tadimeti S. Rao Ph.D.Chief Scientific Officer
  • Mr. Jim KerrChief of Manufacturing & Product Development
  • Dr. Chengzhi Zhang Ph.D.Chief Chemist
  • Dr. Chris M. Storgard M.D.Chief Medical Officer